Currently, some anti-IL-17A (secukinumab, ixekizumab, bimekizumab, brodalumab, etc.)and anti-IL-23A (ustekinumab) monoclonal antibodies are used for the treatment of different autoimmune disorders including IBD, ulcerative colitis, psoriasis arthritis, rheumatoid arthritis, etc.52,53. The gene discussed is IL17A; the disease is ulcerative colitis.